Navigation Links
Lexicon Pharmaceuticals Appoints Dr. Pablo Lapuerta Chief Medical Officer
Date:3/24/2011

THE WOODLANDS, Texas, March 24, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that Pablo Lapuerta, M.D. has joined the company as its chief medical officer, responsible for directing clinical development of Lexicon's drug candidates from Phase 2 proof-of-concept through Phase 3 and approval.  Dr. Lapuerta has 15 years of pharmaceutical industry experience in a variety of leadership roles in drug development, global medical affairs and outcomes research strategy across multiple therapeutic areas, including cardiovascular disease, endocrinology, gastroenterology, and neurology.  Most recently, Dr. Lapuerta served as vice president at Bristol-Myers Squibb where he was responsible for global development of an Alzheimer's disease drug candidate with the associated use of an innovative biomarker.

(Photo:  http://photos.prnewswire.com/prnh/20110324/DA71095)

"Dr. Lapuerta's extensive experience in clinical development, regulatory strategy, and medical affairs are especially valuable as we progress the four programs we currently have in mid-stage clinical studies," said Dr. Arthur T. Sands, president and chief executive officer of Lexicon.  "His breadth of knowledge in multiple therapeutic areas meshes well with Lexicon's broad pipeline in drug discovery and development."

Dr. Lapuerta obtained his undergraduate degree from Harvard College and his medical degree from Harvard Medical School. He completed his training in internal medicine at the University of North Carolina at Chapel Hill followed by a post-doctoral research fellowship at the University of California at Los Angeles in neuroscience. He served as assistant professor at the University of Southern California School of Medicine for several years. He has published more than 50 scientific articles on a wide range of topics including clinical trials, drug safety, epidemiology, health economics, and quality of care.

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has four drug candidates in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking" statements, including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2010, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... 2016  Specialty Silicone Fabricators is offering teachers ... a cleanroom works. The free visual aid provides ... technology. Chris Mazelin , ... SSF enthusiastically supports the Science, Technology, Engineering and ... next generation of innovators. We want to provide ...
(Date:5/3/2016)... 2016 Norgine B.V. ... einen entscheidenden Meilenstein durch diese Veröffentlichung zur  ... Handeln, um Patientenresultate  bei Verdauungs- und Lebererkrankungen ... im Verständnis der Hepatischen Enzephalopathie bei und ... Hepatische Enzephalopathie in der Öffentlichkeit zu schaffen ...
(Date:5/2/2016)... May 2, 2016  While nearly three-quarters of Americans ... have on their health, only about half report taking ... the results of a new survey announced today by ... start of National Osteoporosis Month, Hologic is raising awareness ... nearly 56 million Americans. Osteoporosis is a ...
Breaking Medicine Technology:
(Date:5/4/2016)... ... May 04, 2016 , ... Francesca Loparco, Co-Founder of Queen City Dream ... a same-day LASIK procedure at Christenbury Eye Center. The entrepreneur struggled with ... her surgery the same day as her in-office consultation and eye exam. Francesca’s eyesight ...
(Date:5/4/2016)... ... May 04, 2016 , ... Pharmacy Times ... that it was chosen as the Pharmaceutical News Provider of the Year in ... acknowledge the hard work and dedication of community members who strive to make ...
(Date:5/4/2016)... ... 04, 2016 , ... Bayco Products has announced the introduction ... flashlights in models NSP-9842XL and NSR-9844XL . , First previewed at SHOT ... 2 included CR-123 batteries to produce up to 650 lumens in a variety ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... billing and compliance. In upcoming months, AudioEducator has lined up some informative training ... is designed to give complete compliance know-how and practical, easy-to-apply advice. , On ...
(Date:5/4/2016)... Boulder City, Nevada (PRWEB) , ... May 04, 2016 , ... ... against bladder infections. Bladder infections, also called UTIs, have plagued people since the ... medicine, millions of women get bladder infections every year. It's not just a matter ...
Breaking Medicine News(10 mins):